KRAS and non-small cell lung carcinoma: To explore the effects of anlotinib combined with KRAS-G12Ci in KRAS-G12Ci resistance settings, we first investigated the inhibitory efficacy of sotorasib across different NSCLC cell lines harboring KRAS-G12C mutations.